Dr Reddy's Laboratories Ltd

Dr Reddy's Laboratories maintains a conservative capital structure with a debt-to-equity ratio of 0.20 and a current ratio of 1.8, indicating adequate short-term liquidity coverage. The balance sheet shows total equity of 378.9 billion INR against total liabilities of 202.3 billion INR, with long-term debt standing at 77.3 billion INR. Despite holding 23.5 billion INR in cash and equivalents, the company reports negative net cash after subtracting total debt, a key flag noted in the risk assessment. Operating cash flow stands at 56.7 billion INR, while free cash flow is 17.1 billion INR, reflecting significant capital expenditures of 38.4 billion INR.

Profitability metrics show a return on equity of 11.07% and a return on assets of 7.22%, suggesting efficient use of shareholder capital and assets. The company generated a gross profit of 206.6 billion INR on revenue of 337.0 billion INR, resulting in a gross margin of approximately 61.3%. Operating income was 43.9 billion INR, leading to a net income of 41.96 billion INR, which indicates tight control over non-operating expenses and taxes. Without cohort median data for direct comparison, these returns appear robust for a mature pharmaceutical entity, though specific industry benchmarks are unavailable in the provided data.

There are no material changes to report for Dr. Reddy's Laboratories Ltd (REDY.NS) in the current analysis period. A review of 17 fields confirmed no significant shifts compared to prior assessments, with four schema-expansion fields excluded from the evaluation. The company's profile remains static, characterized by a single analyst following the stock and three top holders. There are no recorded officers in the current dataset, and the firm maintains zero index memberships. Market activity has been entirely absent, with zero dispatches recorded daily from June 25, 2026, through July 15, 2026. This lack of news flow indicates a period of quiet trading and minimal external commentary. Consequently, there are no new developments to interpret regarding the company's financials, estimates, or ESG metrics. Investors should note that the absence of signals suggests stability rather than volatility, though it also implies a lack of fresh catalysts in the immediate term.